ZURZUVAE (zuranolone) CIV, a landmark treatment for women with postpartum Depression, available in the U.S.
On Dec. 14, 2023, Biogen and Sage Therapeutics announced ZURZUVAE (zuranolone) 50 mg (two 25 mg capsules per…
On Dec. 14, 2023, Biogen and Sage Therapeutics announced ZURZUVAE (zuranolone) 50 mg (two 25 mg capsules per…
On Aug. 4, 2023, Biogen and Sage Therapeutics announced that the U.S. Food and Drug Administration (FDA) had…
On Oct. 27, 2020, a National Institutes of Health (NIH) study of 5,000 women found that approximately 1…
On Oct. 13, 2020, NeoGenomics announced plans to open a state-of-the-art research laboratory in China in association with…
On Sept. 29, 2020, Oxford Immunotec announced that it had received clearance from the FDA to amend the…
On Dec. 3, 2014, Fred Eshelman, CEO and founder of Wilmington-based PPD Inc. and a member of the…
On May 21, 2008, the North Carolina School of Pharmacy was renamed the Eshelman School of Pharmacy in…